NCT03709446View on ClinicalTrials.gov

Leflunomide in Previously Treated Metastatic Triple Negative Cancers

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Breast NeoplasmsBreast DiseasesMetastatic Triple Negative Breast Cancer
Interventions
DRUG

Leflunomide

Single agent leflunomide

Trial Locations (3)

10011

Mt Sinai Chelesa, New York

10019

Mt Sinai West, New York

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Joseph Sparano

OTHER

NCT03709446 - Leflunomide in Previously Treated Metastatic Triple Negative Cancers | Biotech Hunter | Biotech Hunter